Yale Trial Validates Immunotherapy Treatment for Non-Small Cell Lung Cancer

The immunotherapy drug atezolizumab improves survival over standard chemotherapy for many patients with newly diagnosed non-small cell lung cancer, according to a new study led by Yale Cancer Center researchers.

Read more

Yale Cancer Center Receives NCI Grant Renewal to Fund Clinical Trials

The National Cancer Institute has awarded a UM1 grant renewal to Yale Cancer Center. The 6-year, $3 million a year grant will fund early phase investigator-initiated clinical trials to develop new potential therapies for treating both solid tumors and hematologic malignancies.

Read more

Dr. Marcella Nunez-Smith Named Director of Center for Community Engagement and Health Equity for Yale Cancer Center and Smilow Cancer Hospital

Marcella Nunez-Smith, MD, MHS, has been appointed Director of the Center for Community Engagement and Health Equity for Yale Cancer Center (YCC) and Smilow Cancer Hospital (SCH), as well as Chief Health Equity Officer & Deputy Chief Medical Officer, at SCH, and Associate Cancer Center Director for Community Outreach and Engagement at YCC.

Read more

Study Shows Clinical Evidence of Anti-Tumor Activity in Patients with Metastatic Castration-Resistant Prostate Cancer

Results of a Phase I clinical trial conducted by researchers at the Yale Cancer Center have shown that ARV-110, an androgen receptor PROTAC® protein degrader, demonstrates anti-tumor responses in patients with metastatic castration-resistant prostate cancer.

Read more

Dr. Mehra Golshan Appointed Deputy Chief Medical Officer for Surgical Services at Smilow Cancer Hospital and Yale Cancer Center

Mehra Golshan, M.D., M.B.A., F.A.C.S., has been appointed the inaugural Deputy Chief Medical Officer for Surgical Services at Smilow Cancer Hospital and Yale Cancer Center, Professor of Surgery at Yale School of Medicine, and Interim Director of the Breast Center at Smilow Cancer Hospital.

Read more

Yale Cancer Center Study Shows Long-Term Survival Benefit for Certain Patients with Advanced Lung Cancer

According to the results of a large, global study led by Yale Cancer Center researchers, even a tiny amount of a biomarker known as PD-L1 (programmed death-ligand1) can predict a long-term survival benefit from using pembrolizumab (Keytruda).

Read more